Vericel to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 27, 2025
Vericel (NASDAQ:VCEL), a leader in advanced therapies for sports medicine and severe burn care markets, has scheduled its fourth-quarter and full-year 2024 financial results announcement for February 27, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vericel (NASDAQ:VCEL), a leader in advanced therapies for sports medicine and severe burn care markets, has scheduled its fourth-quarter and full-year 2024 financial results announcement for February 27, 2025. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss financial results and business highlights. The presentation will be accessible through the company's Investor Relations website, with slides available during the call. A replay of the webcast will remain available until February 27, 2026.
Details
News Market Reaction – VCEL
The recorded move for VCEL in the trading session of this news was +1.41%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its fourth-quarter and full-year 2024 financial results on Thursday, February 27, 2025. Vericel’s management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights.
The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. Please visit the site at least 15 minutes prior to the scheduled start time in order to register and download the required audio software, if necessary. Presentation slides for the conference call will be available on the webcast and on the Investor Relations section of the Vericel website.
To participate by telephone, please register here to receive dial-in details and your personal passcode. A replay of the webcast will be available on the Vericel website until February 27, 2026.
About Vericel Corporation
Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to
Epicel and MACI are registered trademarks of Vericel Corporation. NexoBrid is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2025 Vericel Corporation. All rights reserved.
Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.